Psoriasis is a chronic inflammatory disease mainly affecting the skin, often linked with conditions like psoriatic arthritis. It is characterised by inflammation and abnormal skin cell differentiation, leading to red, scaly plaques. There is an urgent need for more effective, specific, long-lasting, safe, and sustainable treatments. This project aimed to develop antisense oligonucleotides (ASOs) using phosphorodiamidate morpholino (PMO) chemistry for treating psoriasis vulgaris. Previous studies provided transcriptome profiles of psoriatic skin, identifying transcripts that are upregulated during the condition. The goal was to inhibit the expression of IL36R, S100A8, and S100A9 using ASOs. We designed and validated PMO-based ASOs that specifically block inflammatory pathways involved in psoriasis. Specifically, we created PMO oligos to skip exons 9 and 10 of IL36R, as well as others to prevent the translation of S100A8 and S100A9. My presentation will cover the design, main features, molecular effects, and effectiveness of PMOS in cellular models of psoriasis. I will also present results from functional studies, highlighting the potential of PMO chemistry as a genomic therapy for psoriasis. Lastly, I will discuss development updates and future directions for PMO-based antisense treatments from a genomic medicine perspective.